A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients
James R. Berenson(Oncotherapeutics (United States)), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), Jacqueline Hilger(Oncotherapeutics (United States)), Ravi Patel(Comprehensive Blood & Cancer Center), Ori Yellin, Eric Wirtschafter(Institute for Myeloma & Bone Cancer Research), Youram Nassir, Russell Mapes(Institute for Myeloma & Bone Cancer Research), Hank H. Yang(Medical Research Associates), Benjamin Eades(James Madison University), Elizabeth Yung, Alberto Bessudo(California Cancer Associates for Research and Excellence), Chien‐Shing Chen(Loma Linda University), Robert Vescio(Royal Adelaide Hospital), Ralph V. Boccia(Center for Cancer and Blood Disorders), James Hilger
Cited by 31
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425